Vishay Intertechnology Inc.

VSH

NYSE; business equipment; SIC 3670, Electronic Components & Accessories; CIK 0000103730

D

fourth fifth of 469 graded peers in business equipment

rank 360 of 469; percentile 76.7; sampling error 2.3 points; lower is stronger

A B C D E

D, the sloth



Scoreboard


Profitability	D percentile 71.2
Solvency	B/C percentile 42.1
Growth and financing	D percentile 66.4
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $4.2B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: dilution, distress
Inputs computable	8 of 13
Graded from	filings received through Feb 13, 2026 280 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$25.06 2026-11-19; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 13, 2026

Vishay Intertechnology, Inc. ("Vishay," the "Company," "we," "us," or "our") manufactures one of the world's largest portfolios of discrete semiconductors and passive electronic components that support innovative designs in the automotive, industrial, computing, consumer, telecommunications, military, aerospace, and healthcare markets. Serving customers worldwide, Vishay brands itself as The DNA of tech.® Semiconductors include MOSFETs, diodes, and optoelectronic components. Passive components include resistors, inductors, and capacitors.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 71.2						
Gross profitability	14.0%	29.3%		77.1	513	2025-12-31
Return on invested capital	not computable	11.0%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(4.6%)	(7.3%)	66.8	567	2025-12-31
Gross margin stability, five years	4.3 pts	2.3 pts	69.6	406	2025-12-31
Solvency, sleeve percentile 42.1					
Altman Z double-prime	3.61	2.19	32.0	517	2025-12-31
Net debt to EBITDA	1.55x	1.08x	58.4	138	2025-12-31
Interest coverage	not computable	4.90x			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	2.62x	1.98x	35.8	601	2025-12-31
Growth and financing, sleeve percentile 66.4					
Revenue growth, three-year compound	(4.3%)	6.6%	79.3	503	2025-12-31
Free cash flow growth, three-year compound	not computable	17.5%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	16.2%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	3.1%	5.1%	53.6	520	2025-12-31
Net share issuance, one year	not computable	0.5%			
two annual share counts are required; found 1					

Among 469 peers

business equipment; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
355	DXC Technology Co. (DXC)	75.6	D	
356	L3Harris Technologies, Inc. (LHX)	75.9	D	
357	Bumble Inc. (BMBL)	76.1	D	
358	Beam Global (BEEM)	76.3	D	short runway, late filer
359	EverCommerce Inc. (EVCM)	76.5	D	
360	Vishay Intertechnology Inc. (VSH)	76.7	D	
361	Bio-Rad Laboratories, Inc. (BIO)	76.9	D	
362	Gen Digital Inc. (GEN)	77.1	D	
363	Automatic Data Processing Inc. (ADP)	77.4	D	fortress balance sheet
364	AmpliTech Group, Inc. (AMPG)	77.6	D	fortress balance sheet
365	Harvard Bioscience Inc. (HBIO)	77.8	D/E	

What the price implies

at the 2026-11-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	95.1%	(2.2%)	89
Distance from 52-week high	(61.4%)	(38.6%)	23
EBIT to enterprise value	not computable	1.8%	
Free cash flow yield	not computable	3.0%	
Book value to price	not computable	0.29	
Sales to price	not computable	0.33	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	not computable	4.3%	
Relative strength against the sector, log excess return	0.40	(0.29)	89
Twelve-month failure probability, CHS model	not computable	0.05%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$1.1B
Operating cash flow, four quarters	$464.2M
Months of runway	not finite
Days since last periodic filing	16 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$97.3M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$594.9M	2025-12-31	2026-02-13	10-K	26-000019
2	assets	us-gaap:Assets	$4.2B	2025-12-31	2026-02-13	10-K	26-000019
3	operating income	us-gaap:OperatingIncomeLoss	$56.9M	2025-12-31	2026-02-13	10-K	26-000019
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$25.5M	2025-12-31	2026-02-13	10-K	26-000019
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$34.5M	2025-12-31	2026-02-13	10-K	26-000019
6	total debt	us-gaap:LongTermDebt	$950.9M	2025-12-31	2026-02-13	10-K	26-000019
7	book equity	us-gaap:StockholdersEquity	$2.1B	2025-12-31	2026-02-13	10-K	26-000019
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$515.0M	2025-12-31	2026-02-13	10-K	26-000019
9	total debt	us-gaap:LongTermDebt	$905.0M	2024-12-31	2026-02-13	10-K	26-000019
10	book equity	us-gaap:StockholdersEquity	$2.0B	2024-12-31	2026-02-13	10-K	26-000019
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$590.3M	2024-12-31	2026-02-13	10-K	26-000019
12	net income	us-gaap:NetIncomeLoss	-$9.0M	2025-12-31	2026-02-13	10-K	26-000019
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$184.3M	2025-12-31	2026-02-13	10-K	26-000019
14	assets	us-gaap:Assets	$4.1B	2024-12-31	2026-02-13	10-K	26-000019
15	revenue	us-gaap:Revenues	$3.1B	2025-12-31	2026-02-13	10-K	26-000019
16	gross profit	us-gaap:GrossProfit	$626.3M	2024-12-31	2026-02-13	10-K	26-000019
17	revenue	us-gaap:Revenues	$2.9B	2024-12-31	2026-02-13	10-K	26-000019
18	gross profit	us-gaap:GrossProfit	$974.5M	2023-12-31	2026-02-13	10-K	26-000019
19	revenue	us-gaap:Revenues	$3.4B	2023-12-31	2026-02-13	10-K	26-000019
20	gross profit	us-gaap:GrossProfit	$1.1B	2022-12-31	2025-02-14	10-K	25-000017
21	revenue	us-gaap:Revenues	$3.5B	2022-12-31	2025-02-14	10-K	25-000017
22	gross profit	us-gaap:GrossProfit	$887.9M	2021-12-31	2024-02-16	10-K	24-000034
23	revenue	us-gaap:Revenues	$3.2B	2021-12-31	2024-02-16	10-K	24-000034
24	current assets	us-gaap:AssetsCurrent	$1.9B	2025-12-31	2026-02-13	10-K	26-000019
25	current liabilities	us-gaap:LiabilitiesCurrent	$720.4M	2025-12-31	2026-02-13	10-K	26-000019
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$892.2M	2025-12-31	2026-02-13	10-K	26-000019
27	liabilities	us-gaap:Liabilities	$2.1B	2025-12-31	2026-02-13	10-K	26-000019

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$224.7M	2025-12-31	2026-02-13	10-K	26-000019
29	operating income	us-gaap:OperatingIncomeLoss	$486.1M	2023-12-31	2026-02-13	10-K	26-000019
30	interest expense	us-gaap:InterestExpense	$25.1M	2023-12-31	2024-02-16	10-K	24-000034
31	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$273.3M	2025-12-31	2026-02-13	10-K	26-000019
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$173.7M	2024-12-31	2026-02-13	10-K	26-000019
33	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$320.1M	2024-12-31	2026-02-13	10-K	26-000019
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$365.7M	2023-12-31	2026-02-13	10-K	26-000019
35	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$329.4M	2023-12-31	2026-02-13	10-K	26-000019
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$484.3M	2022-12-31	2025-02-14	10-K	25-000017
37	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$325.3M	2022-12-31	2025-02-14	10-K	25-000017
38	current assets	us-gaap:AssetsCurrent	$1.9B	2024-12-31	2026-02-13	10-K	26-000019
39	current liabilities	us-gaap:LiabilitiesCurrent	$708.3M	2024-12-31	2026-02-13	10-K	26-000019
40	assets	us-gaap:Assets	$4.2B	2023-12-31	2026-02-13	10-K	26-000019
41	assets	us-gaap:Assets	$3.9B	2022-12-31	2025-02-14	10-K	25-000017
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	150,916,175	2011-02-24	2011-02-25	10-K	11-000309

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.